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A B S T R A C T
Objectives: Oxaliplatin-induced neurotoxicity can be a dose-limiting side effect to effective chemotherapy. Acute
hyperexcitability causes cold-evoked sensory and motor symptoms, which resemble neuromyotonia. An acces-
sible and non-invasive technique for early detection could help select patients for potential treatments. We
assessed the use of a simple surface electromyography (sEMG) in patients directly after oxaliplatin infusion.
Methods:In patients with colorectal cancer, acute neurotoxicity was evaluated by means of a physical ex-
amination, a questionnaire, and sEMG directly after the second and fourth cycle of oxaliplatin. Questionnaires
were also assessed 1 day after infusion.
Results: 14 patients were measured after the second cycle and 8 patients were also measured after the fourth
cycle of oxaliplatin. All patients reported to a variable degree oxaliplatin induced neurotoxicity symptoms:
sensitivity to touching cold or swallowing cold items were reported as most severe. Clinical signs of hyper-
excitability were observed in 55% of the measurements. Spontaneous activity compatible with neuromyotonia
was observed in 82% of the sEMG recordings.
Conclusions: Patient reported symptoms, physical examination and simple sEMG are complementary mea-
surements to detect acute oxaliplatin induced neurotoxicity. After further validation, sEMG recording can be
used as a simple objective screenings tool to detect nerve hyperexcitability directly after oxaliplatin adminis-
tration.
1. Introduction
Oxaliplatin is a third generation platinum based antineoplastic
agent used for treating gastrointestinal cancer [1–3]. Up to 68.1% of the
patients treated with oxaliplatin progressively suffer from neuropathy
[4]. This neuropathy presents with an acute form, which is character-
ized by peripheral nerve hyperexcitability immediately after adminis-
tration of oxaliplatin, and a chronic form that manifests as a sensory
neuronopathy involving the dorsal root ganglia [5,6]. Both these forms
can induce symptoms that are severe enough necessitating dose re-
duction and even premature discontinuation of treatment [7–10].
The acute neuropathy occurs in about 90% of the patients im-
mediately after infusion of the drug. It will often diminish over the next
days, only to reappear during the next infusion of oxaliplatin [11,12].
Symptoms include cold-induced paresthesia or dysesthesia of the ex-
tremities and the perioral or laryngeal region, accompanied by
fasciculations, and muscular cramps [12–15]. The mechanism for the
acute neurotoxicity is a sodium channelopathy [16–19]. This acute
neurotoxicity shows substantial similarities with the clinical and elec-
trophysiological presentation of neuromyotonia [15,20] a disease also
caused by hyperexcitability of the peripheral axon due to channelo-
pathy. This hyperexcitability is usually confirmed with needle electro-
myography (nEMG) examination of muscles, when repetitive myokymic
discharges and neuromyotonic runs can be observed [20]. It can also be
demonstrated by a newer technique called threshold tracking, but this
is currently limited to research settings only [21].
Previous studies used nerve conduction studies (NCS) [20,22,23],
nEMG [15,20], high-density surface electromyography (HD-sEMG)
[24], and threshold tracking [21] for measuring oxaliplatin-induced
neuropathy, but these methods are either not very sensitive for de-
tecting acute hyperexcitability or focus on chronic neuropathy that
occurs over time with oxaliplatin use (NCS), or invasive (nEMG), or too
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labor intensive for clinical use (HD-sEMG, threshold tracking). Very
little is known yet about the ability of simple 2-channel surface elec-
tromyography (sEMG) to detect nerve hyper excitability [25–27]. Bi-
polar surface recording of muscle activity is a noninvasive, low-cost,
and fast technique for collecting information on muscle activation. In
oxaliplatin-induced neurotoxicity (OIN), sEMG may easily help to select
patients for potential treatments that can reduce the acute symptoms
[28,29].
In this prospective feasibility pilot study, we enrolled patients with
colorectal adenocarcinoma, all receiving intravenous oxaliplatin treat-
ment every 3 weeks. Acute neurotoxicity was assessed clinically di-
rectly after oxaliplatin infusion in cycle 2 and 4 by a standard neuro-
logical examination and questionnaire. A simple 2-channel sEMG signal
was recorded from a single hand muscle. As a proof of principle test, our
aim was to determine whether a short, simple and non-invasive sEMG
measurement would be able to detect nerve hyper excitability in pa-
tients with acute OIN. Additionally, we evaluated if clinical symptoms
correlated with sEMG findings.
2. Materials and methods
2.1. Participants
Participants were recruited prospectively from December 2015 until
April 2017. Eligible participants were aged≥18 years, and received an
oxaliplatin containing chemotherapy regimen for the (curative of pal-
liative) treatment of colorectal adenocarcinoma. Exclusion criteria in-
volved pre-existing neuropathy of any cause, previous systemic che-
motherapy, a history of chronic pain syndrome, use of opioid analgesics
≥6 months, diabetes mellitus, alcoholism or inability to comply with
testing procedures or to give informed consent. The study population
was recruited from the Medical Oncology outpatient department setting
at the Radboud university medical center, Nijmegen, the Netherlands.
The study protocol was approved by the institutional review board of
Medical Ethical Committee of Arnhem/Nijmegen and participants
provided informed consent to use their data. The chemotherapy re-
gimen consisted of intravenous oxaliplatin (130mg/m2) with or
without bevacizumab (7.5mg/kg) in cycles of 3 weeks, which was
followed by capecitabine (1000mg/m2) orally twice daily for 14 con-
secutive day. Dose reductions were applied (25% reduction) when
participants reported grade≥3 toxicities according to National Cancer
Institute-Common Toxicity Criteria.
2.2. Measurements to detect acute neurotoxicity
Measurements to detect acute neurotoxicity were carried out during
cycle 2 and 4 of the oxaliplatin treatment, since from cycle 2 on most
patients tend to experience acute OIN symptoms [12]. Day 0 is directly
after oxaliplatin infusion, and day 1 is 24 h after oxaliplatin infusion.
On day 0 after cycle 2 and 4 sEMG recordings, a questionnaire and a
standardized physical examination were performed. The questionnaire
was repeated during a telephone interview on day 1.
2.2.1. Surface EMG recording
Participants remained fully dressed for this part of the study and
were placed supine on the examination table upon a heated undersur-
face set at 37 °C placed below the bed sheet in order to keep the skin
temperature> 30 °C during sEMG measurements. The sEMG signal was
recorded from the left first dorsal interosseus muscle, in a tendon-belly
montage with the active electrode over the motor point, using reusable
stainless steel disc surface electrodes (Kendall TM H59 P Cloth
Electrodes, 1 cm diameter). The screen time base was set at 100ms/
division and the amplitude was set at 20 μV/division. Participants were
instructed to relax their arm and hand, using direct feedback from the
running EMG signal played over 2 loudspeakers, and additional support
of a small pillow for the hand if needed. EMG signals were captured
from the muscle for a period of 2min, using a Synergy EDX EMG ma-
chine (Natus Neurology Incorporated, Middleton, Wisconsin USA), and
stored as "liveplay" files for offline analysis. As a quality control mea-
sure, 2 participants in whom spontaneous activity was detected during
the measurement were asked and agreed to also undergo a single 30
gauge concentric nEMG exam of the left first dorsal interosseus muscle,
measuring another 2min of spontaneous activity at rest. Signals were
exported for visual and auditive readback using the videocapture mode
of the EMG machine during replay of the recorded signal. Videos were
captured as. avi files, in addition captured signals were exported as.
wav files for further quantitative analysis.
2.2.2. Questionnaire
Patient reported outcomes (PRO) of OIN were assessed: the degree
of sensitivity when touching cold objects or swallowing cold food/
drinks, throat complaints, the pain score in hands and feet [12]. These
items were scored using a numeric rating scale (NRS) from 0 (= no
problem) to 10 (=major problem) [30].
2.2.3. Physical examination
The presence of calf fasciculations, action myotonia in the hands
and eyelids was examined. The participant sat on a chair and the right
calf was inspected for 1min, followed by active plantar flexion of the
right foot for 30 s and again a visual inspection of the right calf for
1min. If voluntary muscle twitching was seen at rest or after muscle
contraction, fasciculations were noted to be present [31]. Eyelid closure
action myotonia was tested by instructing the participant to close the
eyes as forcefully as possible for 10 s and then rapidly to open their eyes
on command, which was repeated 5 times. The time from the command
to open the eyes was timed, and action myotonia was present if re-
laxation time was> 1 s during any of the trials [32]. Hand-grip action
myotonia was tested by instructing the participant to forcefully close
the fingers of the right hand in a fist for 10 s, and then rapidly open the
fist on command, which was repeated 5 times. The time from the
command to open the right fist until relaxation of the handgrip muscles
was timed and action myotonia was present if relaxation time was> 1 s
during any of the trials [32].
2.3. Data analysis
The clinical data collection was stored in a Castor database (Castor
EDC 2017.6.1, Ciwit B.V.) and transferred to a SPSS Statistics file
(version 22.0, IBM Corporation, Armonk, NY, USA) for analysis.
Categorical data were presented as counts and percentages of cases,
continuous variables were presented as mean ± SD, and skewed data
were presented as median with interquartile range. As all analyses re-
late to comparisons within participants, paired t-test were used for
analysis. The correlation between PRO and AUC of sEMG was analyzed
using the Spearman’s rank correlation coefficient. A P value< 0.05 was
considered to be statistically significant. Figures were created using
GraphPad Prism, Version 5.03 (GraphPad Software Inc., La Jolla, CA,
USA).
Qualitative analysis of the sEMG data was performed twice, by
offline playback of the captured EMG signals from the Synergy live play
files and by revision from signal from the videocaptured.avi files.
Signals were screened by the traditional method of visual and auditive
inspection by an experienced clinical neurophysiologist (NvA). The
presence or absence of any spontaneous muscle activity and any vo-
luntary contraction activity was scored in a yes/no fashion and the type
of activity (e.g. fasciculation potentials, myotonic runs, myokymic
discharges, neuromyotonic discharges) was noted according to standard
clinical practice as described by for example Preston and Shapiro [33].
Endplate noise (i.e. low-amplitude monophasic negative potentials with
an irregular firing rate between 20–40 Hz) was ignored. Quantitative
AUC analysis of sEMG data was performed using a dedicated software
script created by one of the authors (JD), using MATLAB version
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R2014b (The Mathworks Inc., version R2014B, Natick, Massachusetts
U.S.A.). Analysis settings were a horizontal time axis of 1000ms
(100ms/division) and a vertical EMG signal amplitude axis of −1mV
to+ 1mV (0.2mV/division). The sEMG signals were rectified, and
divided in 1 s epochs (10 divisions) per screen. Each epoch was
manually scored for the presence of spontaneous activity by another
author (NvA). Subsequently, the area under the curve (AUC) of the
rectified signal was calculated above a noise threshold of 0.05mV.
3. Results
Fourteen participants were included in the study (Table 1). All were
measured for the first time after their second oxaliplatin infusion, and 8
participants were also measured a second time after the fourth infusion.
3.1. Surface EMG recording
Spontaneous activity was found in 18 of the total of 22 (82%) sEMG
recordings. It was found 12 times during the first measurement and 6
times during the second measurement. The spontaneous activity ob-
served consisted of myokymic discharges and/or neuromyotonic runs of
varying amplitudes and durations; no other phenomena were observed.
Examples of electrical discharges are shown in Fig. 1. This spontaneous
activity was present in all participants measured only once. In 6 out of 8
participants who could be assessed twice the results were congruent,
showing the presence (5/8) or absence (1/8) of spontaneous activity
during both measurements. In 1 participant the activity was absent
during the first measurement and present during the second. In the final
participant measured twice, the second measurement could not be as-
sessed for spontaneous activity because of continuous motor unit acti-
vation which could not be voluntary stopped by the participant. Needle
EMG examination in 2 participants with myokymic discharges and/or
neuromyotonia corroborated the surface data findings. Quantitative
analysis showed that the AUC of the spontaneous activity varied widely
between measurements (Median 1.6mV/s, IQR 0.7–5.7) (Table 2).
3.2. Patient reported outcomes
All participants (100%) experienced at least 1 acute neuropathy
symptom during treatment with oxaliplatin. Only 1 participant reported
no symptoms directly after the second cycle of oxaliplatin, though this
participant did experience acute symptoms on the following day. Most
symptoms, besides throat discomfort during cycle 4, increased in se-
verity the day after oxaliplatin administration. There was a wide in-
terindividual variability in grading of each symptom. For all 4 mea-
surements sensitivity to touching and swallowing cold were rated
significantly higher than the remaining components of the PRO
(P=0.033 for cycle 4, day 0; P < 0.001 for all other moments; mean
differences ranged between 3 and 5) (Fig. 2).
3.3. Physical examination
Clinical signs of hyperexcitability were found in 12 of the 22 ex-
aminations (55%). During the physical exam after the second treatment
cycle, 8 of the 14 participants showed signs of increased nerve hyper-
excitability, with fasciculations in 7 participants, eyelid closure action
myotonia in 1 participant, and hand-grip action myotonia in 1 parti-
cipant. After the fourth cycle, 4 of the 8 participants showed clinical
Table 1
Clinical characteristics of patients. M=Male, F= female, BMI=Body Mass Index, CAPOX=Capecitabine-Oxaliplatin, BEVA=Bevacizumab.
Patient
no.
Sex / Age(yr) BMI Treatment/ Cancer stage Intent Cumulative dose oxaliplatin (mg/m2)
Cycle 2 Cycle 4
Measurement performed
Cycle 2 Cycle 4
1 M/53 27.8 CAPOX T3N2M0 Curative 260 520 + +
2 M/72 24.6 CAPOX-BEVA T3N0M1 Palliative 260 455 + +
3 M/63 25.5 CAPOX T3N2M0 Curative 260 520 + −, technical error
4 F/68 29.8 CAPOX-BEVA T4N1M1 Palliative 260 – + −, died after cycle 2
5 M/65 25.8 CAPOX-BEVA T3/N1M1 Palliative 260 – + −, stop after cycle 3, general weakness
6 F/48 30.0 CAPOX T4N1M0 Curative 260 487.5 + +
7 F/65 19.5 CAPOX-BEVA T3N1M1 Palliative 260 520 + +
8 M/63 21.3 CAPOX T4N1M0 Curative 227.5 422.5 + +
9 M/67 22.6 CAPOX-BEVA T4N2M1 Palliative 260 – + −, stop after cycle 3, general weakness
10 M/53 28.8 CAPOX-BEVA T3N1M1 Palliative 260 455 + −, general weakness
11 M/71 23.6 CAPOX-BEVA T2N1M1 Palliative 227.5 422.5 + +
12 M/33 24.9 CAPOX T4N2M0 Curative 260 520 + +
13 F/74 25.1 CAPOX T4N1M0 Curative 260 520 + −, severe neuropathy
14 F/47 37.9 CAPOX-BEVA TxN1M1 Palliative 260 487.5 + +
Fig. 1. A panel showing the different forms of spontaneous activity
(A= several multiplets, B= a neuromyotonic run, C= a combination of re-
petitive multiplets and a neuromyotonic run). Time scale horizontal axis: 1 s,
vertical amplitude scale 20 μV/division.
Table 2
Results of quantitative analysis of spontaneous activity (AUC in mV/s of the
rectified surface EMG signal).
Patient no. Cycle 2
Spontaneous
activity (mV/s)
Cycle 4
Spontaneous
activity (mV/s)
1 23.2 2.1
2 1.6 0.0
3 11.1
4 0.7
5 8.1
6 1.0 0.4 (75% oxaliplatin)
7 2.1 0.1
8 0.0 0.0 (75% oxaliplatin)
9 25.9
10 1.3
11 0.7 0.3 (75% oxaliplatin)
12 0.0 3.2
13 3.3
14 1.0 0.2 (75% oxaliplatin)
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increased nerve hyperexcitability, with fasciculations in 3 participants
and hand-grip action myotonia in 1 participant.
3.4. Surface EMG recording and clinical measurements
All but 1 participant who had spontaneous activity on sEMG re-
ported neuropathy symptoms directly after oxaliplatin treatment. No
correlation with the AUC of the sEMG signal and any of the neuropathy
symptom on D0 or D1 was found (Rho= 0.312, P= 0.098 for throat
discomfort on Day 0; the P value of the Pearson correlation for all other
neuropathy symptoms with AUC had higher P values). In 10 out of 18
measurements in which spontaneous activity on sEMG was found,
clinical signs of hyperexcitability were observed. Thus, during 8 mea-
surements where spontaneous activity was found on sEMG, no clinical
signs of increased hyperexcitability were noticed. In 2 participants who
had no spontaneous activity on sEMG, fasciculations were observed
during the physical examination.
4. Discussion
This study demonstrates that a simple 2-channel sEMG study of the
first dorsal interosseus muscle is a feasible and non-invasive method to
screen for objective signs of nerve hyperexcitability directly after ox-
aliplatin administration. All participants reported to a variable degree
symptoms of acute OIN; and signs of nerve hyperexcitability could be
detected with physical examination in 55%, which was less sensitive
than the sEMG (82% detection). Surface EMG recordings may have
missed spontaneous discharges from motor units lying deep in the
muscle, which hampers a 100% detection rate.
Other studies have established the presence of neuromyotonic dis-
charge patterns within 1–4 days after the first oxaliplatin administra-
tion by performing nEMG of different leg muscles [15,20,34]. In 100%
of the participants spontaneous high frequency discharges were found
in 1 or more muscles when 3 muscles were sampled [15]. We explored a
simplified method and found spontaneous activity in 82% of the sEMG
measurements of the first dorsal interosseus muscle within 1–2 h after
the second or fourth oxaliplatin infusion. Although nEMG corroborated
our sEMG results in 2 participants, further study is needed to determine
the optimal muscle sample size to detect hyperexcitability. In line with
previous observations, participants reported cold evoked symptoms as
most severe [7,12,16,22]. Contrary to other reports [10,12], there was
a slight decrease in severity of symptoms during the fourth cycle,
probably caused by dose reduction in some participants and by other
participants dropping out the study. The severity of the acute symptoms
has been shown to be one of the risk factors for developing high grade
chronic OIN [35], so monitoring and preferably treating these of
symptoms is of paramount importance to ensure chemotherapy com-
pliance. A recent study demonstrated that motor nerve hyperexcit-
ability was correlated with acute cold induced symptoms in 12 patients
within 3 days after oxaliplatin infusion [19], though we did not find
this. Our study has some limits. We excluded patients with a preexistent
neuropathy, and we did not perform a baseline physical neurologic
examination. The major aim of our study methodology was focused on
detecting signs of hyperexcitability and normally no hyperexcitability is
present in patients, although theoretically this could have biased our
results. Also, during the second measurement 6/14 patients dropped
out of the study due to a worsening clinical status, which may have
influenced characteristics of the PRO, the physical examination and
sEMG results. Finally, we did not perform serial measurements on
consecutive days after oxaliplatin administration, so it is unknown if
repeated measurements could improve the detection rate further and
how the hyperexcitability evolves over time. In conclusion, 2-channel
sEMG is a simple, non-invasive and feasible screening tool to comple-
ment the subjective reported symptoms for monitoring nerve hyper-
excitability after oxaliplatin infusion. Surface EMG improves the ob-
jective detection of hyperexcitability compared with the physical
examination. Further validation of the technique and studying a pos-
sible correlation with chronic OIN and sEMG findings can help guide in
future intervention studies.
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